A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland
- PMID: 15328493
A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland
Abstract
Background: Metamizole is a common analgesic and antipyretic drug. However, its use has been associated with a risk of side-effects involving agranulocytosis and aplastic anemia. These reactions are rare and unpredictable. The aim of this prospective study was to evaluate the risks of these complications in Poland, where this medication is available without prescription.
Material/methods: Six hematological centers, serving approximately 40% (ca. 15 million people) of the country's population, participated in the study. All cases of agranulocytosis and aplastic anemia were recorded and their severity and association with the use of drugs, especially metamizole sodium, were evaluated. All the patients receiving cytostatic or immunosuppressive drugs were excluded.
Results: During the 12 months of the study, 2 cases of aplastic anemia and no cases of agranulocytosis were confirmed which may have been associated with the use of metamizole. Overall, we recorded 16 cases of agranulocytosis and 27 cases of aplastic anemia. The two cases of metamizole sodium-induced aplastic anemia were non-fatal in character.
Conclusions: Considering the consumption of 112,300,094 tablets of metamizole in Poland a year, the figures obtained result in an incidence of 0.25 cases of aplastic anemia per 1 million persons per day of treatment; this value being less than that for other nonsteroidal anti-inflammatory drugs. Nevertheless, caution is recommended in the application of metamizole, particularly over long periods and in large doses.
Similar articles
-
Population-based drug-induced agranulocytosis.Arch Intern Med. 2005 Apr 25;165(8):869-74. doi: 10.1001/archinte.165.8.869. Arch Intern Med. 2005. PMID: 15851637
-
Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole).Eur J Clin Pharmacol. 2002 Jul;58(4):265-74. doi: 10.1007/s00228-002-0465-2. Epub 2002 Jun 6. Eur J Clin Pharmacol. 2002. PMID: 12136373
-
The incidence of metamizole sodium-induced agranulocytosis in Poland.J Int Med Res. 2002 Sep-Oct;30(5):488-95. doi: 10.1177/147323000203000504. J Int Med Res. 2002. PMID: 12449518
-
Metamizole (Dipyrone) and the Liver: A Review of the Literature.J Clin Pharmacol. 2019 Nov;59(11):1433-1442. doi: 10.1002/jcph.1512. Epub 2019 Aug 21. J Clin Pharmacol. 2019. PMID: 31433499 Review.
-
Neutropenia, agranulocytosis and dipyrone.Sao Paulo Med J. 2005 Sep 1;123(5):247-9. doi: 10.1590/s1516-31802005000500009. Epub 2005 Dec 8. Sao Paulo Med J. 2005. PMID: 16358101 Free PMC article. Review.
Cited by
-
Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.Br J Clin Pharmacol. 2012 Dec;74(6):999-1004. doi: 10.1111/j.1365-2125.2012.04304.x. Br J Clin Pharmacol. 2012. PMID: 22519658 Free PMC article. Clinical Trial.
-
Acute intermittent porphyria: analgesia can be dangerous.BMJ Case Rep. 2019 Sep 30;12(9):e231133. doi: 10.1136/bcr-2019-231133. BMJ Case Rep. 2019. PMID: 31570358 Free PMC article.
-
[Metamizole (dipyrone): mode of action, drug-drug interactions, and risk of agranulocytosis].Schmerz. 2014 Dec;28(6):584-90. doi: 10.1007/s00482-014-1490-7. Schmerz. 2014. PMID: 25199942 Review. German.
-
Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years.Front Endocrinol (Lausanne). 2023 Jan 27;14:1064723. doi: 10.3389/fendo.2023.1064723. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36777352 Free PMC article.
-
Novel bioactive metabolites of dipyrone (metamizol).Bioorg Med Chem. 2012 Jan 1;20(1):101-7. doi: 10.1016/j.bmc.2011.11.028. Epub 2011 Nov 25. Bioorg Med Chem. 2012. PMID: 22172309 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
